𝔖 Bobbio Scriptorium
✦   LIBER   ✦

CD5 positive immunoregulatory B cell subsets

✍ Scribed by Teresa Paglieroni; Vincent Caggiano; Malcolm Mackenzie


Publisher
John Wiley and Sons
Year
1988
Tongue
English
Weight
206 KB
Volume
28
Category
Article
ISSN
0361-8609

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


CD5 positive immunoregulatory B cells in
✍ Dr. Malcolm R. MacKenzie; Teresa Paglieroni; Vincent Caggiano πŸ“‚ Article πŸ“… 1991 πŸ› John Wiley and Sons 🌐 English βš– 332 KB

CD19+CD5+ lymphocytes constitute a minority of peripheral blood B cells. In view of the importance of these cells in the pathogenesis of the immunoregulation of myeloma, their incidence in another lymphoid organ was determined. CD5+ B cells were studied in 9 spleens from patients with multiple myelo

Immunoregulatory T Cell Subsets in Chron
✍ Fredric G. Regenstein; Stanford T. Roodman; Robert P. Perrillo πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 393 KB πŸ‘ 2 views

The purposes of this study were 2-fold: (i) To enumerate peripheral immunoregulatory T cell subsets in untreated patients with chronic hepatitis B virus (HBV) infection and (ii) to examine the relationship between disturbances in the balance of lymphocyte subsets with liver disease and the presence

CD5+ B-cell networks
✍ John F. Kearney πŸ“‚ Article πŸ“… 1993 πŸ› Elsevier Science 🌐 English βš– 631 KB
The therapeutic effect of rituximab on C
✍ Rie Hyo; Naoto Tomita; Kengo Takeuchi; Tomohiro Aoshima; Atsuko Fujita; Hideyuki πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 111 KB

## Abstract The prognosis of diffuse large B‐cell lymphoma (DLBCL) has improved markedly in recent years of rituximab era. The prognosis of __de novo__ CD5‐positive DLBCL is reported to be poor, but the effect of rituximab on this type of lymphoma remains unclear. To investigate the effect of ritux